Skip to main content

Abbott Laboratories will acquire Cardiovascular Systems in deal worth $890 million

The deal for New Brighton-based Cardiovascular Systems is expected to improve Abbott's portfolio of devices that treat vascular disease.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.